NCT05348200Phase 2Completed

Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

Study sponsor: Citius Pharmaceuticals, Inc. · CTXR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-04-20Actual

Enrollment · participants304Actual

Source updated2023-08-31Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Hemorrhoids

Treatments or interventions studied

Monad 1DrugAlso known as Lidocaine
Monad 2DrugAlso known as Halobetasol Propionate (HBP)
Monad 3DrugAlso known as Halobetasol Propionate
Combination - CITI-002 (low dose)DrugAlso known as CITI-002 L
Combination - CITI-002 (high dose)DrugAlso known as CITI-002 H

Primary outcomes · main study measures

measure: Change in Hemorrhoid symptoms; description: Change in hemorrhoidal symptoms (pain, burning, itching, and swelling) as measured by the patient using a numeric rating scale.; timeFrame: Day 8

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history